ATE551361T1 - Mutante des granulozytenkoloniestimulierenden faktors (g-csf) und chemisch konjugiertes polypeptid davon - Google Patents
Mutante des granulozytenkoloniestimulierenden faktors (g-csf) und chemisch konjugiertes polypeptid davonInfo
- Publication number
- ATE551361T1 ATE551361T1 AT06783354T AT06783354T ATE551361T1 AT E551361 T1 ATE551361 T1 AT E551361T1 AT 06783354 T AT06783354 T AT 06783354T AT 06783354 T AT06783354 T AT 06783354T AT E551361 T1 ATE551361 T1 AT E551361T1
- Authority
- AT
- Austria
- Prior art keywords
- csf
- residue
- mutant
- cysteine
- stimulating factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050065746A KR100735784B1 (ko) | 2005-07-20 | 2005-07-20 | 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물 |
| PCT/KR2006/002841 WO2007011166A1 (en) | 2005-07-20 | 2006-07-19 | Mutant of granulocyte-colony stimulating factor(g-csf) and chemically conjugated polypeptide thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE551361T1 true ATE551361T1 (de) | 2012-04-15 |
Family
ID=37669016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06783354T ATE551361T1 (de) | 2005-07-20 | 2006-07-19 | Mutante des granulozytenkoloniestimulierenden faktors (g-csf) und chemisch konjugiertes polypeptid davon |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8841426B2 (de) |
| EP (2) | EP2174951B1 (de) |
| JP (1) | JP4782834B2 (de) |
| KR (1) | KR100735784B1 (de) |
| CN (2) | CN102153643B (de) |
| AT (1) | ATE551361T1 (de) |
| ES (2) | ES2428863T3 (de) |
| WO (1) | WO2007011166A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0605684D0 (en) * | 2006-03-21 | 2006-05-03 | Sicor Biotech Uab | Method For Purifying Granulocyte-Colony Stimulating Factor |
| WO2008147534A1 (en) * | 2007-05-22 | 2008-12-04 | Maxygen Holdings Ltd. | Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant |
| JP5594691B2 (ja) * | 2008-03-17 | 2014-09-24 | 独立行政法人理化学研究所 | 改変タンパク質 |
| WO2009139784A1 (en) * | 2008-05-13 | 2009-11-19 | Nora Therapeutics, Inc. | Human g-csf analogs and methods of making and using thereof |
| EP3225248B1 (de) * | 2008-07-23 | 2023-06-07 | Ambrx, Inc. | Modifizierte bovine g-csf-polypeptide und ihre verwendung |
| TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
| EP2709669A1 (de) * | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Verfahren zur aufrechterhaltung der pegylierung von polypeptiden |
| AU2018348138A1 (en) * | 2017-10-11 | 2020-04-23 | Ambrx, Inc. | Porcine G-CSF variants and their uses |
| US11732016B2 (en) | 2017-12-27 | 2023-08-22 | Council Of Scientific & Industrial Research | Polypeptide exhibiting granulocyte-colony stimulating factor activity |
| CN116334057B (zh) * | 2022-08-16 | 2024-07-19 | 北京理工大学 | 一种利用聚乙二醇马来酰亚胺衍生物构建的酶组装体及其制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| EP0347041A3 (de) * | 1988-05-13 | 1990-11-22 | Amgen Inc. | Zusammensetzungen und Verfahren zur Behandlung oder Verhütung von Infektionen bei Tieren |
| GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
| US5104651A (en) * | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
| US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| JP3708151B2 (ja) * | 1994-12-15 | 2005-10-19 | 協和醗酵工業株式会社 | Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法 |
| US6066318A (en) * | 1995-10-05 | 2000-05-23 | G.D. Searle & Co. | Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors |
| KR100230579B1 (ko) | 1997-04-23 | 1999-12-01 | 허영섭 | 과립구 콜로니 자극인자를 발현하는 재조합 미생물 및 그로부터 전기 재조합 단백질의 제조방법 |
| US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| BR9812267B1 (pt) * | 1997-07-14 | 2013-11-26 | Hormônio de crescimento recombinante. | |
| KR100260350B1 (ko) * | 1998-02-09 | 2000-07-01 | 허영섭 | 과립구 콜로니 자극인자의 유도체 단백질을 생산하는 재조합 미생물 및 그로부터 전기 재조합 단백질의 제조방법 |
| EP1144613B2 (de) | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Verfahren zur herstellung von proteinen mit freien cysteinresten |
| US6646110B2 (en) | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
| JP2003519478A (ja) | 2000-01-10 | 2003-06-24 | マキシゲン・ホールディングズ・リミテッド | Ｇ−ｃｓｆ結合体 |
| US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
| US6602498B2 (en) * | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| AU2003210052A1 (en) * | 2002-03-20 | 2003-09-29 | Biopolymed Inc. | Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue |
| JP4412461B2 (ja) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
| KR20040083268A (ko) * | 2003-03-21 | 2004-10-01 | 한미약품 주식회사 | 안정성이 증가된 인간 과립구 콜로니 자극인자 융합체 및이의 제조방법 |
-
2005
- 2005-07-20 KR KR1020050065746A patent/KR100735784B1/ko active Protection Beyond IP Right Term
-
2006
- 2006-07-19 EP EP09010623.8A patent/EP2174951B1/de active Active
- 2006-07-19 CN CN2010106059142A patent/CN102153643B/zh active Active
- 2006-07-19 AT AT06783354T patent/ATE551361T1/de active
- 2006-07-19 CN CNA2006800239675A patent/CN101213208A/zh active Pending
- 2006-07-19 WO PCT/KR2006/002841 patent/WO2007011166A1/en active Application Filing
- 2006-07-19 JP JP2008522703A patent/JP4782834B2/ja active Active
- 2006-07-19 ES ES09010623T patent/ES2428863T3/es active Active
- 2006-07-19 ES ES06783354T patent/ES2381256T3/es active Active
- 2006-07-19 US US11/995,968 patent/US8841426B2/en active Active
- 2006-07-19 EP EP06783354A patent/EP1919945B1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070010817A (ko) | 2007-01-24 |
| EP2174951A2 (de) | 2010-04-14 |
| ES2428863T3 (es) | 2013-11-12 |
| WO2007011166A1 (en) | 2007-01-25 |
| EP1919945A1 (de) | 2008-05-14 |
| EP1919945B1 (de) | 2012-03-28 |
| JP4782834B2 (ja) | 2011-09-28 |
| EP1919945A4 (de) | 2009-02-18 |
| CN102153643B (zh) | 2012-12-12 |
| JP2009501789A (ja) | 2009-01-22 |
| EP2174951A3 (de) | 2010-07-07 |
| KR100735784B1 (ko) | 2007-07-06 |
| CN102153643A (zh) | 2011-08-17 |
| CN101213208A (zh) | 2008-07-02 |
| US8841426B2 (en) | 2014-09-23 |
| EP2174951B1 (de) | 2013-09-11 |
| ES2381256T3 (es) | 2012-05-24 |
| US20080200657A1 (en) | 2008-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE551361T1 (de) | Mutante des granulozytenkoloniestimulierenden faktors (g-csf) und chemisch konjugiertes polypeptid davon | |
| ES2950789T3 (es) | Polipéptidos de apelina | |
| HK1115154A1 (en) | Glycosylated il-7, preparation and uses | |
| EP1778842B8 (de) | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung | |
| ATE417595T1 (de) | Keratin-bindende polypeptide | |
| AU2003264514A8 (en) | Wt1 substitution peptides | |
| DK1877435T3 (da) | Glucagon-lignende peptid 2 (GLP-2)-analoger | |
| JP2013543497A5 (de) | ||
| IL147293A0 (en) | Peptides that lower blood glucose levels | |
| CN103415300A (zh) | N-末端修饰的fgf21化合物 | |
| CY1106723T1 (el) | Ν-τελικα μονοπεγυλιωμενα συζευγματα ανθρωπινης αυξητικης ορμονης, διεργασιες για την παρασκευη τους και μεθοδοι χρησης αυτων | |
| ES2689781T3 (es) | Angiotensina en el tratamiento de afecciones cerebrales | |
| WO2006113681A3 (en) | Plant-derived elastin binding protein ligands and methods of using the same | |
| MX2009012675A (es) | Tensioactivos reconstituidos que tienen propiedades mejoradas. | |
| HK1128924A1 (en) | Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same sparc | |
| CY1112867T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια | |
| DE60324406D1 (de) | Modifizierter faktor viii | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| CN105949322A (zh) | 一种适用于“一步法”改性医用钛基材料的生物模拟活性肽 | |
| DE60143818D1 (de) | Alpha-fetoprotein-peptide und ihre verwendung | |
| EP1796707A4 (de) | Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren | |
| NZ591827A (en) | Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject | |
| HUP0303430A2 (hu) | Csökkentett immunogenitású, módosított protamin | |
| RU2002115633A (ru) | Конъюгаты интерферона | |
| RU2005102040A (ru) | Искусственная биокожа "ростоши" |